Amifostine (Ethyol®): Dosing, administration and patient management guidelines

European Journal of Cancer

Volumn 32, Issue SUPPL. 4, 1996, Pages

  Bukowski, R M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

administration guidelines; amifostine; cancer

Indexed keywords

AMIFOSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER; CLINICAL TRIAL; DRUG TOXICITY; HUMAN; HYPOTENSION; PRIORITY JOURNAL; VOMITING; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG ANTAGONISM; PRACTICE GUIDELINE; REVIEW;

AMIFOSTINE; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOTENSION;

EID: 34547648732     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00328-0     Document Type: Article

References (11)

1. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy
2. Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection
3. High dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancer
4. Biological characteristics of some improved radioprotectors
5. Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine
6. Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide
7. Phase I study of WR-2721 and carboplatin
8. Phase I clinical trial of cisplatin, WR-2721, and the murine monoclonal antibody R24 in patients with metastatic melanoma: clinical and biologic effects
9. A randomized trial of cyclophosphamide and cisplatin ± amifostine in the treatment of advanced epithelial ovarian cancer (abstract)
10. Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent)